Switch theme
Sign up to access all valuation multiples
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
1991
233
LTM Revenue $20.5M
Last FY EBITDA -$34.9M
$26.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CASI Pharmaceuticals has a last 12-month revenue (LTM) of $20.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, CASI Pharmaceuticals achieved revenue of $28.5M and an EBITDA of -$34.9M.
CASI Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CASI Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $20.5M | XXX | $28.5M | XXX | XXX | XXX |
| Gross Profit | $9.2M | XXX | $11.1M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$34.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -122% | XXX | XXX | XXX |
| EBIT | -$36.3M | XXX | -$39.2M | XXX | XXX | XXX |
| EBIT Margin | -177% | XXX | -137% | XXX | XXX | XXX |
| Net Profit | -$36.3M | XXX | -$39.3M | XXX | XXX | XXX |
| Net Margin | -177% | XXX | -138% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, CASI Pharmaceuticals's stock price is $1.
CASI Pharmaceuticals has current market cap of $20.6M, and EV of $26.4M.
See CASI Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.4M | $20.6M | XXX | XXX | XXX | XXX | $-2.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, CASI Pharmaceuticals has market cap of $20.6M and EV of $26.4M.
CASI Pharmaceuticals's trades at 0.9x EV/Revenue multiple, and -0.8x EV/EBITDA.
Equity research analysts estimate CASI Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CASI Pharmaceuticals has a P/E ratio of -0.6x.
See valuation multiples for CASI Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20.6M | XXX | $20.6M | XXX | XXX | XXX |
| EV (current) | $26.4M | XXX | $26.4M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.8x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCASI Pharmaceuticals's last 12 month revenue growth is -70%
CASI Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
CASI Pharmaceuticals's rule of 40 is -133% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CASI Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CASI Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -70% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -122% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -133% | XXX | -192% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 176% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CASI Pharmaceuticals acquired XXX companies to date.
Last acquisition by CASI Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . CASI Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CASI Pharmaceuticals founded? | CASI Pharmaceuticals was founded in 1991. |
| Where is CASI Pharmaceuticals headquartered? | CASI Pharmaceuticals is headquartered in United States of America. |
| How many employees does CASI Pharmaceuticals have? | As of today, CASI Pharmaceuticals has 233 employees. |
| Who is the CEO of CASI Pharmaceuticals? | CASI Pharmaceuticals's CEO is Dr. Wei-Wu He. |
| Is CASI Pharmaceuticals publicy listed? | Yes, CASI Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of CASI Pharmaceuticals? | CASI Pharmaceuticals trades under CASI ticker. |
| When did CASI Pharmaceuticals go public? | CASI Pharmaceuticals went public in 1996. |
| Who are competitors of CASI Pharmaceuticals? | Similar companies to CASI Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CASI Pharmaceuticals? | CASI Pharmaceuticals's current market cap is $20.6M |
| What is the current revenue of CASI Pharmaceuticals? | CASI Pharmaceuticals's last 12 months revenue is $20.5M. |
| What is the current revenue growth of CASI Pharmaceuticals? | CASI Pharmaceuticals revenue growth (NTM/LTM) is -70%. |
| What is the current EV/Revenue multiple of CASI Pharmaceuticals? | Current revenue multiple of CASI Pharmaceuticals is 1.3x. |
| Is CASI Pharmaceuticals profitable? | Yes, CASI Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
